These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 18409934)
21. Monitoring method for surface contamination caused by selected antineoplastic agents. Larson RR; Khazaeli MB; Dillon HK Am J Health Syst Pharm; 2002 Feb; 59(3):270-7. PubMed ID: 11862639 [TBL] [Abstract][Full Text] [Related]
22. Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces. Mucci N; Dugheri S; Farioli A; Garzaro G; Rapisarda V; Campagna M; Bonari A; Arcangeli G Med Pr; 2020 Sep; 71(5):519-529. PubMed ID: 32667290 [TBL] [Abstract][Full Text] [Related]
23. Utilization of the solid sorbent media in monitoring of airborne cyclophosphamide concentrations and the implications for occupational hygiene. Odraska P; Dolezalova L; Piler P; Oravec M; Blaha L J Environ Monit; 2011 May; 13(5):1480-7. PubMed ID: 21468422 [TBL] [Abstract][Full Text] [Related]
24. Studies on the decontamination of surfaces exposed to cytotoxic drugs in chemotherapy workstations. Roberts S; Khammo N; McDonnell G; Sewell GJ J Oncol Pharm Pract; 2006 Jun; 12(2):95-104. PubMed ID: 16984748 [TBL] [Abstract][Full Text] [Related]
25. Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study. Berruyer M; Tanguay C; Caron NJ; Lefebvre M; Bussières JF J Occup Environ Hyg; 2015; 12(2):87-94. PubMed ID: 25105559 [TBL] [Abstract][Full Text] [Related]
26. A quantitative LC-MS method to determine surface contamination of antineoplastic drugs by wipe sampling. Kåredal M; Jönsson R; Wetterling M; Björk B; Hedmer M J Occup Environ Hyg; 2022 Jan; 19(1):50-66. PubMed ID: 34723774 [TBL] [Abstract][Full Text] [Related]
27. [Investigation on occupational exposure to 5-fluorouracil in pharmacy intravenous admixture service of a hospital]. Huang YW; Zhang NH; Tong DM; Feng X; Zhang MB; He JL Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2010 Jun; 28(6):414-7. PubMed ID: 21033150 [TBL] [Abstract][Full Text] [Related]
28. Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning. Chu WC; Hon CY; Danyluk Q; Chua PP; Astrakianakis G J Oncol Pharm Pract; 2012 Mar; 18(1):46-51. PubMed ID: 21737485 [TBL] [Abstract][Full Text] [Related]
29. Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Hedmer M; Tinnerberg H; Axmon A; Jönsson BA Int Arch Occup Environ Health; 2008 Jul; 81(7):899-911. PubMed ID: 18066576 [TBL] [Abstract][Full Text] [Related]
30. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Schmaus G; Schierl R; Funck S Am J Health Syst Pharm; 2002 May; 59(10):956-61. PubMed ID: 12040735 [No Abstract] [Full Text] [Related]
31. Pilot study: External surface contamination of gemcitabine and 5-fluorouracil on drug packaging. Kåredal M; Özdemir J; Tinnert A; Wetterling M; Hedmer M J Oncol Pharm Pract; 2024 Jan; 30(1):9-14. PubMed ID: 36916178 [TBL] [Abstract][Full Text] [Related]
32. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. Siderov J; Kirsa S; McLauchlan R J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949 [TBL] [Abstract][Full Text] [Related]
33. Quantification of healthcare workers' exposure to cyclophosphamide, ifosfamide, methotrexate, and 5-fluorouracil by 24-h urine assay: A descriptive pilot study. Palamini M; Dufour A; Therrien R; Delisle JF; Mercier G; Gagné S; Caron N; Bussières JF J Oncol Pharm Pract; 2020 Dec; 26(8):1864-1870. PubMed ID: 32138611 [TBL] [Abstract][Full Text] [Related]
34. UPLC-MS/MS method for simultaneous determination of cyclophosphamide, docetaxel, doxorubicin and 5-fluorouracil in surface samples. da Silva CB; Julio IP; Donadel GE; Martins I J Pharmacol Toxicol Methods; 2016; 82():68-73. PubMed ID: 27521053 [TBL] [Abstract][Full Text] [Related]
35. Levels and risks of surface contamination by thirteen antineoplastic drugs in the Czech and Slovak hospitals and pharmacies. Doležalová L; Bláhová L; Kuta J; Hojdarová T; Kozáková Š; Bláha L Environ Sci Pollut Res Int; 2022 Apr; 29(18):26810-26819. PubMed ID: 34855176 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs. Ursini CL; Cavallo D; Colombi A; Giglio M; Marinaccio A; Iavicoli S Int Arch Occup Environ Health; 2006 Nov; 80(2):134-40. PubMed ID: 16761155 [TBL] [Abstract][Full Text] [Related]
37. Hygienic guidance values for wipe sampling of antineoplastic drugs in Swedish hospitals. Hedmer M; Wohlfart G J Environ Monit; 2012 Jul; 14(7):1968-75. PubMed ID: 22692549 [TBL] [Abstract][Full Text] [Related]
38. Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. Hon CY; Teschke K; Chu W; Demers P; Venners S J Occup Environ Hyg; 2013; 10(7):374-83. PubMed ID: 23668810 [TBL] [Abstract][Full Text] [Related]
39. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542 [TBL] [Abstract][Full Text] [Related]
40. Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Hon CY; Teschke K; Demers PA; Venners S Ann Occup Hyg; 2014 Jul; 58(6):761-70. PubMed ID: 24644303 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]